Rheumatology

Advances in Biologic Therapy for RA

Paul Emery, MD; Leonard Calabrese, DO; Mark Genovese, MD; Marc C. Levesque, MD, PhD

Course Chair: Paul Emery, MD Arthritis Research UK Professor of Rheumatology Director - Leeds Musculoskeletal Biomedical Research Unit, LTHT Director of Institute Rheumatic and Musculoskeletal Medicine University of…

Best of RA Forum: Applying Immunologic Approaches in RA Management – A Call to Arms

Joe Craft, MD; Leonard H. Calabrese, DO

Learning Objectives: Upon successful completion of this educational activity, participants should be better able to:

Best of RA Forum™ 2014

Leonard H. Calabrese, DO; Jeffrey Curtis, MD, MS, MPH; M. Elaine Husni, MD, MPH; Jonathan Kay, MD

Learning Objectives: Upon successful completion of this educational activity, participants should be better able to:

Best of RA Forum™ 2016

Leonard H. Calabrese, DO; Joseph E. Craft, MD ; William F.C. Rigby, MD

Learning Objectives: Upon successful completion of this educational activity, participants should be better able to:

Cardiovascular Disease in Rheumatoid Arthritis: Impact, Risk Factors, Treatment and Prevention

Jon T. Giles, MD, MPH

Release Date: April 16, 2014 Termination Date: April 15, 2015 This enduring material is approved for 1 year from the date of original release.

Cardiovascular Disease, a systemic manifestations of RA

Ernest Choy

Release Date: July 17, 2014 Termination Date: July 16, 2015 This enduring material is approved for 1 year from the date of original release.

Combining Biologics and Small Molecules?

Leonard H. Calabrese, DO; John Tesser, MD

Learning Objectives: Upon successful completion of this educational activity, participants should be better able to examine the immunopathogenesis and therapeutic landscape of RA and allied conditions, as well as…

Complement in Rheumatic Disease

William FC Rigby, MD

Learning Objectives: Upon successful completion of this educational activity, participants should be better able to examine the basic biologic principles underlying autoimmune and inflammatory diseases.

Effectiveness of Tocilizumab in Monotherapy and in Combination with Different Synthetic DMARDs: A Registry-based Comparison Study

Cem Gabay, MD

Release Date: December 29, 2013 Termination Date: December 28, 2014 This enduring material is approved for 1 year from the date of original release.

Fixed Versus On-flare Retreatment with Rituximab in RA: Results from the Cererra Collaboration

Katerina Chatzidionysiou, MD

Release Date: January 22. 2014 Termination Date: January 21, 2015 This enduring material is approved for 1 year from the date of original release.

Hot Topics in RA: Debates and Discussion from Rome

Eric M. Ruderman, MD; Leonard H. Calabrese, DO; Stanley B. Cohen, , MD; Jeffrey Curtis, MD, MS, MPH

Learning Objectives: Upon successful completion of this educational activity, participants should be better able to:

Impact of Inadequate Response to Prior Biologic Agents on Abatacept Drug Retention in Rheumatoid Arthritis Patients: A Pan-European Analysis of RA Registries

Axel Finckh, MD, PhD

Release Date: January 22, 2014 Termination Date: January 21, 2015 This enduring material is approved for 1 year from the date of original release.

Initial Evaluation of Patient with Osteoarthritis

Introduction Osteoarthritis (OA) is the most common form of joint disease affecting humans.1 OA rarely occurs in people under the age of 40, and the prevalence is steadily increasing as the population ages.2 Also…

Loss of Response

Allan Gibofsky, MD, JD, MACR, FACP, FCLM ; Jonathan Kay, MD

Learning Objectives: Upon successful completion of this educational activity, participants should be better able to examine the immunopathogenesis and therapeutic landscape of RA and allied conditions, as well as…

New Data and Hot Topics in Rheumatoid Arthritis: Highlights from EULAR 2016

Leonard H. Calabrese, DO; Eamonn Molloy, MD, MS, FRCPI ; Allan Gibofsky, MD, JD, MACR, FACP, FCLM

Learning Objectives: Upon successful completion of this educational activity, participants should be better able to:

OA and Obesity: More Than Mechanical

Timothy McAlindon, MD, MPH

Written by Timothy McAlindon, MD, MPH The content contained in this article is taken from Chronic OA Management; Volume 1, Issue 2 Obesity and knee osteoarthritis (OA) are among the most common comorbid chronic…

On the Scenes at EULAR: Updates on Current and Emerging Therapies

Philip G. Conaghan, MBBS, PhD, FRACP, FRCP; Tom W. J. Huizinga, MD, PhD

Learning Objectives: Upon successful completion of this educational activity, participants should be better able to evaluate the evolving role of B cell targeting, T cell targeting, small molecules, and other novel…

Pathogenesis of Osteoarthritis

Robert T. Keenan MD, MPH

Written by Robert T. Keenan MD, MPH Introduction Degenerative joint disease is a descriptive synonym for osteoarthritis (OA). Key characteristics of OA are changes in subchondral bone, osteophyte formation, subchondral…

Pathogenesis of Rheumatoid Arthritis 2016

Leonard H. Calabrese, DO

The past decade has witnessed a revolution in our understanding and approach to rheumatoid arthritis. Among the key events has been an evolution of our understanding of the preclinical phase of rheumatoid arthritis,…

Prediction of 52-Week Treatment Response Based on a Week 12 Assessment in Rheumatoid Arthritis Patients Receiving Certolizumab Pegol: Comparison of a Patient-reported Instrument Versus Physician-based Disease Activity Assessment

Jeffrey R. Curtis, MD, MPH, MS

Release Date: December 29, 2013 Termination Date: December 28, 2014 This enduring material is approved for 1 year from the date of original release.

Principles of Gene Therapy and Its Future Role in OA

Rebecca Gordon, MD

Rebecca Gordon, MD Ronald Reagan UCLA Medical Center Los Angeles, California Santa Monica-UCLA Medical Center and Orthopaedic Hospital Santa Monica, California Introduction Osteoarthritis (OA) is a chronic, debilitating…

RA Forum Pre-study: Applying Immunologic Management Approaches in Rheumatoid Arthritis

Leonard H. Calabrese, DO

Learning Objectives: Upon successful completion of this educational activity, participants should be better able to:

RA Patient with a History of Malignancy

Jonathan Kay, MD; John Tesser, MD

Learning Objectives: Upon successful completion of this educational activity, participants should be better able to examine the immunopathogenesis and therapeutic landscape of RA and allied conditions, as well as…

Rare and Serious Adverse Events

Leonard H. Calabrese, DO; Elizabeth Kirchner, MSN, CNP

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its…

Rational Use of Disease Activity Measurement and Treat-to-Target

Martin Jan Bergman, MD, FACR, FACP, FCPP

Release Date: May 20, 2014 Termination Date: May 19, 2015 This enduring material is approved for 1 year from the date of original release.

Rheumatoid Arthritis and Allied Conditions

Leonard H. Calabrese, DO; John Tesser, MD

Learning Objectives: Upon successful completion of this educational activity, participants should be better able to examine the immunopathogenesis and therapeutic landscape of RA and allied conditions, as well as…

Rheumatoid Arthritis: Mechanisms of Autoimmunity, Immunogenicity, and Advances in Immunotherapy

Leonard H. Calabrese, DO; Jonathan Kay, MD; Gregg J. Silverman, MD

Learning Objectives: Upon successful completion of this educational activity, participants should be better able to:

Secondary OA due to Hemochromatosis

William F. Harvey, MD, MSc, FACR

Faculty: William F. Harvey, MD, MSc, FACR Assistant Professor of Medicine Tufts Medical Center Tufts University School of Medicine Boston, MA

Th17 Cells in Health and Disease

Christopher T. Ritchlin, MD, MPH

Learning Objectives: Upon successful completion of this educational activity, participants should be better able to examine the basic biologic principles underlying autoimmune and inflammatory diseases.

Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis of Long-term Clinical Trial Safety Data in Patients with Rheumatoid Arthritis

Mark C. Genovese, MD

Release Date: January 22, 2014 Termination Date: January 21, 2015 This enduring material is approved for 1 year from the date of original release.

Treating TNF Non-responders

Jonathan Kay, MD; Leonard H. Calabrese, DO

Learning Objectives: Upon successful completion of this educational activity, participants should be better able to examine the immunopathogenesis and therapeutic landscape of RA and allied conditions, as well as…

Treatment Discontinuation

Leonard H. Calabrese, DO; Allan Gibofsky, MD, JD, MACR, FACP, FCLM

Learning Objectives: Upon successful completion of this educational activity, participants should be better able to examine the immunopathogenesis and therapeutic landscape of RA and allied conditions, as well as…

Treatment Escalation in a Newly Diagnosed Patient

Leonard H. Calabrese, DO

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its…

Treatment with Small Molecules

Leonard H. Calabrese, DO; John Tesser, MD

Learning Objectives: Upon successful completion of this educational activity, participants should be better able to examine the immunopathogenesis and therapeutic landscape of RA and allied conditions, as well as…